Annual Meeting 2025, findings were shown from the Phase IIIa REDEFINE 2 trial, assessing Novo Nordisk’s fixed-dose ...

Over the last four years, weight-loss drugs that dampen down appetite and promote satiety have revolutionised obesity ...

Novo Nordisk , looking to turn around slowing growth of its blockbuster weight-loss drug Wegovy, plans to test whether its ...

Novo Nordisk’s injectable amylin alternative to Wegovy appears to have underperformed the approved obesity blockbuster in a ...

Novo Nordisk stock rises as its next-generation subcutaneous obesity treatment candidate, cagrilintide, delivers meaningful ...

Novo Nordisk is broadening its focus beyond obesity and diabetes by exploring the potential of its weight-loss drugs, ...

The sub-analysis, presented at the European Association for the Study of Diabetes congress, showed improved safety data to ...

By contrast, Eli Lilly was cut to “hold” from “buy,” with its target reduced to $830 from $970. The analysts said the obesity ...

Novo Nordisk leads globally in GLP-1s despite U.S. pressure, with a strong pipeline, cost cuts, and attractive valuation.

Eli Lilly's strong Q2 results, raised guidance, and robust demand for tirzepatide reinforce confidence in its commercial ...

Novo Nordisk today released promising late-stage trial results for its CagriSema - a fixed-dose combination of semaglutide ...

Although cagrilintide from Novo Nordisk A/S proved less than impressive when paired with GLP-1 agonist semaglutide in a single drug known as Cagrisema, the dual long-acting amylin analogue and ...